Post by Merck Life Science

Congratulations to Hiba Therapeutics Inc., winner of the 2026 North American Advance Biotech Grant! Through its TROIKA platform, Hiba Therapeutics is advancing a targeted approach designed to activate tumor-resident T cells, with the potential to address key challenges in solid tumor treatment while helping reduce systemic toxicity. As part of the grant, the team will gain access to our expertise and resources, including support through the M Lab Collaboration Center and Emprove Program, to help accelerate scale-up and manufacturing readiness. Since 2014, the Advance Biotech Grant program has supported more than 40 startups globally, helping innovators bring promising therapies closer to patients. Learn more: http://ms.spr.ly/6046vo7Pe